Trial Profile

An International Multi-centre Randomised Phase II Study to Assess the Efficacy of TAK228 in Combination With Intravenous Weekly Paclitaxel Compared With Weekly Paclitaxel Alone in Women With Advanced/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 30 Sep 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sapanisertib (Primary) ; Paclitaxel
Indications Carcinoma; Fallopian tube cancer; Glandular and epithelial neoplasms; Ovarian cancer; Peritoneal cancer; Sarcoma
Focus Therapeutic Use
Acronyms DICE

20 Sep 2024 Status changed from active, no longer recruiting to completed.
22 Mar 2024 This trial has been completed in Germany, according to European Clinical Trials Database record.
05 Apr 2022 Trial design published in the Trials

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com